Raloxifene on Coagulation System in the Postmenopausal Women

Study Overview
=================
Brief Summary
-----------------
Objective: The aim of this study is to assess the effects of raloxifene HCl on coagulation parameters in healthy postmenopausal women. Material and method: 80 healthy postmenopausal women were evaluated at Karadeniz Technical University Hospital at gynecology out-patient clinic from December 2005 to December 2006. Local institutional ethics committee approved our study protocol and written informed consent was obtained from all participants before enrollment. All patients received daily 600 milligrams of calcium and 400 international units of vitamin D (Cal-D-VİTA, Roche Switzerland,). 60 milligrams of raloxifene HCI, which is a selective estrogen receptor modulator (SERM), was added to treatment protocol if patients required hormonal therapy. Patients receiving raloxifene therapy in addition to calcium and vitamin D therapy formed the study group(n=50). Control group (n=30) was made up of the patients only receiving calcium and vitamin D. Factor 8, von Willebrand factor, protein C, protein S, antithrombin- III and fibrinogen levels were measured in all patients before treatment. These measurements were repeated at three and twelve months after treatment. Comparisons were performed with Student t test or Mann Whitney test between the two groups and two-way ANOVA within the groups. Proportions were compared with Fisher exact or Chi-square tests. Statistically analysis was done with SPSS packet program (SPSS 11; SPSS Inc.) All p values were two-tailed and p<0.05 was considered statistically significant.

Official Title
-----------------
The Effect of Raloxifene on the Parameters of Coagulation System in the Postmenopausal Women

Conditions
-----------------
Raloxifene, Postmenopausal Women

Intervention / Treatment
-----------------
* Diagnostic Test: coagulation system parameters; factor 8, von Willebrand factor, protein C, protein S, antithrombin III and fibrinogen were studied.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In the study planned on patients who have not had menstruation for at least one year, or who have been in menopause naturally or surgically, the presence of menopause was accepted if the patients' FSH level was> 40 IU / L. Verbal and written consent was obtained from all patients included in the study. Exclusion Criteria: . Hypertension, diabetes mellitus, hypercholesterolemia, presence of hepatic-renal-thyroid-parathyroid-adrenal diseases, cardiovascular, cerebrovascular and thromboembolic diseases, undiagnosed vaginal bleeding, presence of hormone-dependent malignancy or anamnesis, presence of varicose veins, chronic drug use that disrupts sex steroid metabolism cases with smoking alcohol use

Ages Eligible for Study
-----------------
Minimum Age: 42 Years
Maximum Age: 62 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group I<br>50 cases who received raloxifene and calcium therapy | Diagnostic Test: coagulation system parameters; factor 8, von Willebrand factor, protein C, protein S, antithrombin III and fibrinogen were studied.<br> <br> |
| group II<br>30 cases who received only calcium therapy | Diagnostic Test: coagulation system parameters; factor 8, von Willebrand factor, protein C, protein S, antithrombin III and fibrinogen were studied.<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measuring coagulation parametres | After collecting all blood, Factor 8, von Willebrand factor, protein C, protein S, antithrombin- III, and fibrinogen levels were measured in all patients. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fibrinogen, raloxifene, coagulation system, von Willebrand factor, Factor 8, vitamin D, protein C, protein S, antithrombin- III